DepYmed to Meet with Investors at the BIO CEO and Investor Conference

2024-02-21

FARMINGDALE, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes. Today the Company announces that management will be meeting with investors at the BIO CEO and Investor Conference held on February 26 – 27, 2024 at the New York Marriott Marquis.

Interested qualified investors must register for the conference via https://bcic.bio.org/registration.

CEO Andreas Grill will be available for one-on-one meetings throughout the conference.

To schedule a meeting: https://bcic.bio.org/bio-one-one-partnering or contact the Company directly at info@depymedinc.com.

About DepYmed, Inc.

DepYmed Inc., is a New York based rare disease and cancer therapeutic development company that was founded to capitalize on the scientific discoveries of the Tonks lab at Cold Spring Harbor Laboratory in the physiological function of PTP1B and ways to modulate its role in various human diseases. DepYmed is currently developing a new class of potent, orally bioavailable small molecule inhibitors of the enzyme PTP1B as novel therapeutics for Rett Syndrome and different types of cancer. In addition, DepYmed has also discovered a novel class of small molecules with copper chelating properties that it is developing as potential therapeutic agents for such diseases as Wilson disease and various cancers. The company is actively developing a deep pipeline of novel compounds with broad therapeutic potential in these emerging drug classes in collaboration with Cold Spring Harbor Laboratory. For more information, please visit the Company’s website at: www.depymed.com.

For Media Inquiries please contact:

Jules Abraham

JQA Partners, Inc.

jabraham@jqapartners.com

917-885-7378

DepYmed:

info@depymedinc.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构